FIVE PATRYS PRODUCTS SHOW CANCER THERAPEUTIC POTENTIAL
November 16th 2008 04:18
Thursday November 13, 2008
Daily news on ASX-listed biotechnology companies
* ASX, BIOTECHS DOWN: LABTECH UP 29%, POLARTECHNICS DOWN 16%
* PROGEN TO GIVE HALF ITS CASH TO SHAREHOLDERS
* FIVE PATRYS PRODUCTS SHOW CANCER THERAPEUTIC POTENTIAL
* INDEPENDENT COMMITTEE BACKS NOVOGEN’S CANCER TRIAL
* 42% OF CLINUVEL OPPOSE DIRECTOR L JACK WOOD’S 350k OPTIONS
* AVEXA PRESENTS PAPERS ON HIV, ANTIBACTERIAL PROGRAMS
* ARANA LOSS UP ON REVENUE UP 14% TO $39.5m
* ARANA’S US PRESIDENT PROMOTED TO ACTING CEO
* 42% OF PROTEOME OPPOSE CEO’S PERFORMANCE RIGHTS
* STEM CELL’S 2nd ASX CASH FLOW QUERY: FUNDS EXPECTED
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
PATRYS
Patrys says five of its lead natural human antibody products “effectively prevented the spread of cancer in preclinical studies”.
Patrys said independent researchers at Germany’s University of Wurzburg’s division of surgical oncology found that in preclinical studies designed to test the ability to prevent the spread of colon cancer to the animal’s liver, 35 percent of the 20 animals treated with lead product PAT-LM1 developed metastases, whereas 85 percent of the 20 animals in the control group developed metastases.
The company said PAT-LM1 was scheduled to enter human clinical trials in 2009.
Patrys said the researchers evaluated four additional Patrys lead products in studies designed to evaluate a product’s ability to prevent the spread of gastric cancer to an animal’s bone marrow and blood, referred to as “recurrence” or “minimal residual disease”.
Patrys said in aggregate, 38 percent of the 47 animals treated in these studies with Patrys products developed minimal residual disease, whereas 73 percent of the 48 animals in the control group developed minimal residual disease.
Patrys said its PAT-SM6 was scheduled to start human clinical trials in 2009 and was “one of the most potent antibodies tested in the gastric cancer studies”.
Surgical oncologist at the University of Wurzburg Dr Bertram Illert, one of the lead investigators for the studies, said the consistency of the results over a significant number of animal experiments “points to the great promise of natural human antibody-based therapies to prevent metastases and recurrence, where products on the market offer little promise.”
“The anti-cancer benefits of natural human antibodies were also seen in the results obtained from a human clinical trial that we conducted with another product developed by Patrys technology, PAT-SC1, where 35 gastric cancer patients treated with a small dose of PAT-SC1 obtained a survival benefit relative to a historic control group of untreated patients,” Dr Illert said.
“In fact, we have just seen one of those treated patients who lived seven years cancer-free, with no recurrence, where without treatment his life expectancy was 15 months,” Dr. Illert said.
Dr Illert also conducted the PAT-SC1 human clinical trial.
Patrys said PAT-SC1 was one of several products generated using Patrys’ natural human antibody technologies that are being developed by larger industry companies, in this case Astrazeneca, the success of which would bring returns to the company.
Patrys head of research Dr H Peter Vollmers said effective treatments could be established by identifying and developing antibodies made by the human immune system that effectively attack and kill cancer cells – as a supplement to cancer patients’ own natural anticancer immunity.
“The positive results from this series of studies provide broad support for this approach,” Dr Vollmers said.
Patrys’s vice-president of research and development Dr Frank Hensel said that all five of the products “demonstrated the ability to prevent the spread of cancer in these preclinical studies” and each product did so through distinct mechanisms, meaning each product kills cancer cells in a unique way.
“Our team and collaborators will continue to study those differences to determine the best clinical uses for each product,” Dr Vollmers said.
Patrys was unchanged at 10 cents.
To read all these articles in full, subscribe to Biotech Daily at the link above or at www.biotechdaily.com.au
| 18 |
| Vote |
Shared on
Add To: 
Subscribe to this blog
